Background: Neoadjuvant systemic therapy (NST) before surgery is a standard option for patients with early breast cancer (EBC) that allows in vivo chemosensitivity testing. Given the promising activity of pemetrexed plus doxorubicin in metastatic breast cancer, it was reasonable to evaluate the utility of this combination as part of an NST regimen in EBC.
introduction Neoadjuvant (preoperative or primary) systemic chemotherapy has been the long-standing treatment of choice for patients with locally advanced breast cancer [1] [2] [3] [4] [5] . In recent years, it has also become a frequently used option in patients with operable early breast cancer (EBC) and clear indication for adjuvant chemotherapy [6, 7] . Although overall no survival advantage for the neoadjuvant treatment approach as compared with adjuvant treatment has been shown in this setting [8, 9] , advantages of neoadjuvant systemic chemotherapy such as the higher rate of breast-conserving surgery [8, [10] [11] [12] and the possibility of in vivo chemosensitivity testing validate its use in EBC.
Neoadjuvant systemic chemotherapy substantially reduces the size of primary tumor and lymph node metastases in >80% of cases, improving operability and increasing the probability of breast-conserving surgery [13] . It also provides the earliest possible systemic treatment against preexisting micrometastases and might be associated with better survival in a subgroup of young women after extended follow-up [14] . Furthermore, neoadjuvant treatment permits a rapid assessment of response of the primary tumor to a particular chemotherapy regimen. This assessment allows the opportunity to cross over to a regimen with non-cross-resistant drugs for an individual patient if there is minimal or no response to the first-line regimen [15] . In separate meta-analyses, neoadjuvant and adjuvant therapy have been shown to produce apparently equivalent survival and disease progression rates [16] , with neoadjuvant therapy associated with higher rates of breastconserving surgery and pathological complete response (pCR) [17] .
The most common approaches are to start neoadjuvant treatment with anthracycline-taxane-based combination regimens or with an anthracycline-based regimen sequentially followed by a taxane either docetaxel every 3 weeks (q3w) or paclitaxel weekly (2009 guidelines of the AGO for diagnosis and treatment of breast cancer version are available at www.agoonline.com). Tumors are well known to be non-cross-resistant with taxanes and anthracycline-based regimens. In patients with advanced breast cancer in whom treatment with anthracycline-based regimens failed, the use of taxanes resulted in overall response rates of 18% to >50% [8] . In two separate phase III trials, neoadjuvant doxorubicin plus cyclophosphamide followed by docetaxel (AC-D) has produced promising results [8, 18] . In the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-27 study, AC-D given before surgery achieved a better overall response rate of 91% (versus 86% with AC alone, P < 0.001) and a higher pCR rate of 26% (versus 14% for AC alone, P < 0.001) [8] . Neoadjuvant AC-D also provided a superior pCR rate of 14% when compared with 7% for dose-dense doxorubicin plus docetaxel in the German Preoperative Adriamycin Docetaxel Study Group (GEPARDUO) trial (odds ratio = 2.2, P < 0.001) [18] .
The achievement of pCR is associated with improved survival [2] . Therefore, pCRs are widely accepted as surrogate markers for survival. However, it must be noted that high pCR rates are mainly observed in patients with hormone receptor (HR)-negative breast cancer either triple negative [estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) negative] or HR negative and HER2 positive. pCR rates in HR-positive breast cancer in general are low, resulting in questions about the benefit of chemotherapy in those patients [19] . Therefore, it is reasonable to evaluate if the introduction of new compounds into sequential standard regimens may increase pCR rates and thereby improve the long-term outcome. Pemetrexed (Eli Lilly and Company, Indianapolis, IN, USA), a folate antimetabolite, inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase. In pretreated advanced breast cancer with and without vitamin supplementation, single-agent pemetrexed achieved response rates in the range of 8%-28% [20] [21] [22] [23] [24] ; in locally advanced breast cancer with vitamin supplementation, the response rate was 31% [25] . In a phase II study, the combination of doxorubicin plus pemetrexed achieved a promising response rate of 56% as first-line chemotherapy [26] .
In this article, we report results from an international, randomized, noncomparative phase II study of the two sequential neoadjuvant chemotherapy regimens doxorubicin plus pemetrexed followed by docetaxel (AP-D) and AC-D, respectively, in patients with primary operable breast cancer T2-T4a-c N0-2 M0. The primary objective of the clinical core protocol was to assess pCR rate in the breast. Secondary objectives included assessments of clinical tumor response, rate of histologically negative axillary lymph nodes, toxicity, and disease-free survival. Both arms were stratified according to hormone receptor (HR) status and enrollment site. An additional translational component of this study, which attempts to identify differentially expressed genes predictive for the achievement of pCR following either AP-D or AC-D, will be the subject of a separate article [27] .
patients and methods
This international, open-label, noncomparative phase II study was carried out in compliance with the principles of good clinical practice, the Helsinki Declaration, and federal and institutional guidelines. Each local institutional review board approved the protocol before study initiation.
eligibility criteria
Women between the ages of 18 and 70 years with histologically confirmed primary invasive breast cancer stages T2-4a-c N0-2 M0 according to the American Joint Committee on Cancer staging system (version 5) [28] and tumor size ‡2 cm, as determined by mammography or magnetic resonance imaging, were included. Patients were also required to have an Eastern Cooperative Oncology Group performance status (ECOG PS) between 0 and 2; adequate organ, including cardiac function; and estimated life expectancy ‡6 months. Patients with HER2-overexpressing disease were eligible for the study. Main exclusion criteria were treatment with an experimental drug within 30 days of study entry, prior anticancer therapy with an anthracycline or other prior antitumor therapy for breast cancer, concurrent antitumor therapy, inflammatory or exulcerating breast cancer, a second primary malignancy [except carcinoma in situ (CIS) of the cervix or adequately treated nonmelanoma skin cancer] unless diagnosed and treated ‡5 years ago with no evidence of recurrence, preexisting sensorial or motor neuropathy (greater than grade 1), and any serious concomitant systemic disorder. Written informed consent was required before study entry, and women of childbearing potential were required to use medically appropriate birth control during and 6 months after treatment.
treatment plan
Eligible patients were stratified according to HR status (classified as positive for at least one HR or negative for both HRs) and to enrollment site, and were randomly assigned to receive either four cycles of pemetrexed 500 mg/ m 2 plus doxorubicin 60 mg/m 2 on day 1 every 21 days followed by four Patients receiving pemetrexed were also required to receive folic acid, vitamin B 12 , and dexamethasone. Oral folic acid (350-1000 lg) had to be started 1-2 weeks before cycle 1 and continued daily until 3 weeks after the last dose of pemetrexed. Vitamin B 12 (1000 lg) was injected i.m. 1-2 weeks before cycle 1 and every 9 weeks thereafter, until 3 weeks after the last dose of pemetrexed. Oral dexamethasone (4 mg) was administered twice daily the day before, the day of, and the day after each pemetrexed dose. When patients received docetaxel, the dexamethasone dose was doubled (8 mg) and also given twice daily the day before, the day of, and the day after each docetaxel dose.
Full-dose chemotherapy was required for cycles 1 and 5 (first cycles of each therapy sequence). Subsequent cycles could be delayed up to 42 days after last chemotherapy and were started only with an absolute neutrophil count (ANC) of ‡1.5 · 10 9 /l and a platelet count of ‡100 · 10 9 /l. Doses in each cycle of the sequence were reduced by 25% based on platelet count nadirs (<50 · 10 9 /l), ANCs (<0.5 · 10 9 /l), febrile neutropenia (ANC <1 · 10 9 /l and fever ‡38.5°C), or infection with grade 3 or 4 neutropenia. In the event of diarrhea requiring hospitalization (or diarrhea of at least grade 3), treatment was delayed until diarrhea resolved before proceeding (up to 42 days). When treatment was resumed, the dose of each drug of the current sequence was reduced by 25%. For all other grade 3 or greater nonhematologic toxicities, treatment was delayed until resolution to grade 1 or less, or to less then or equal to the patient's original baseline grade before proceeding (up to 42 days), and dose reduced by 25% or 40% as deemed appropriate by the treating physician. After neoadjuvant systemic therapy (NST), patients without evidence of disease progression received routine surgery, preferably no later than 42 days after the last dose of chemotherapy.
assessments
Baseline radiological tumor measurements and ultrasound were carried out within 4 weeks before enrollment. Mammography or breast magnetic resonance imaging was required. For radiological tumor measurement, the same method used at baseline was required for on-study evaluations after the first treatment sequence (four cycles of AP or AC, respectively) and before surgery. A physical examination was carried out for clinical measurement of palpable tumor lesions within 2 weeks of enrollment, before every cycle, and before surgery.
The diagnosis of invasive carcinoma was established before chemotherapy by needle core biopsy. Tumor type and tumor grading were determined on this biopsy, as well as ER, PgR, and HER2 status. Surgical breast and axillary lymph node resection specimens were evaluated for pathological tumor response. For pathological evaluation after chemotherapy, all tissue from the tumor bed was embedded as a rule and the cellularity assessed as previously described [29] . pCR was defined as the absence of invasive carcinoma in the breast.
end points
The primary end point was to evaluate pCR rate in the breast at the time of surgery using criteria of the NSABP [10] . To qualify for pCR evaluation, acquisition of an adequate specimen upon surgery and treatment with at least one dose of the assigned study drug were required. All pCR evaluations were reviewed by a central pathologist. Because nodal status has shown to be highly correlative to pCR in the breast [8] , the rate of histologically negative axillary lymph node status was also assessed. pCR and other efficacy variables were reported in terms of number of patients qualified for each particular analysis. Clinical response was defined according to RECIST 1.0 and was assessed after the first sequence (following four cycles) and second sequence (after completion) of chemotherapy in both treatment arms [30] . Response confirmation was not required. Toxic effects were measured according to version 3.0 of the Common Terminology Criteria for Adverse Events [31] . Patients in both treatment arms were also followed for disease-free survival, which was defined as the time from the date of study enrollment (i.e. randomization) to the first date of progressive disease or death from any cause.
statistical considerations
This study was conducted in two stages [32] . During the first stage, 42 qualified patients were evaluated per treatment arm. If fewer than five patients experienced a pCR, accrual was to be stopped in that treatment arm and the conclusion drawn that the regimen was not worthy of further study in this tumor type. If five or more patients responded, accrual continued until a minimum of 121 qualified patients were included. The regimen was considered promising and worthy of future study if responses were seen in at least 18 of 121 assessable patients (pCR rate ‡14.9%). The probability of stopping early after stage I was at least 59% if the true pCR rate was £10% (H0), and the statistical power was above 90% when the true pCR rate was 20%. Assuming a 5% dropout rate before pCR evaluation, the target sample size was 128 patients per treatment arm. This sample size allowed selection of the regimen that achieved a numerically superior pCR rate. For example, if there was ‡10% difference between the true pCR rates of the regimens, and assuming the pCR rate was 10% in the arm with the lowest rate (implying true pCR rates of 10% and 20%, respectively), there was an 88% probability of correctly selecting the superior regimen. The assessment of treatment-specific pCR rates overall and pCR rates by HR status was prospectively planned and reported. Figure 1 . The reasons for discontinuation of the 19 patients before randomization were as follows: 11 due to entry criteria not met, 5 due to patient decision, 2 due to physician decision, and 1 due to protocol violation. One patient randomly assigned to receive AP-D was treated with AC-D. Per protocol, this patient was excluded from efficacy analysis but was included in safety analysis for AC-D. At study discontinuation, investigators documented the primary reason for ending study participation. Of the 135 patients randomly assigned to AP-D group, 26 discontinued for other reasons than study completion, including 12 due to adverse event, 3 due to physician decision, 7 due to lack of efficacy/progressive disease, and 4 due to patient decision. Of the 122 patients randomly assigned to AC-D group, 17 discontinued for reasons other than study completion, including 9 due to adverse event, 3 due to physician decision, 3 due to lack of efficacy/progressive disease, 1 due to patient decision, and 1 due to sponsor decision.
baseline characteristics and dose administration Table 1 summarizes patient and disease characteristics at baseline by treatment group for all patients randomly allocated. Overall, patients were overwhelmingly of Caucasian origin (98.8%) and in good physical health (ECOG PS 0 = 94.9%). Generally, treatment arms were similar with respect to disease characteristics. Table 2 . Dose reductions were documented in 10.2% of AP cycles, 10.5% of subsequent docetaxel cycles, 5.8% of AC cycles, and 11.4% of subsequent docetaxel cycles. Primary reasons for dose reductions in both treatment groups were impaired liver function and neutropenia.
efficacy Following enrollment of 42 protocol-qualified patients in each treatment arm, an interim assessment determined that there were 7 pCRs in the AP-D group and 13 in the AC-D group. Thus, pCR rates in both treatment arms were sufficient for the study to proceed to full accrual.
Main efficacy results are summarized in Table 3 . Two hundred forty-six patients qualified for pathological response evaluation. The pCR rates were 16.5% [95% confidence interval (CI) 10. Table 4 summarizes pCR rates by HR status. Among patients receiving AP-D, pCR rate did not vary by HR status: patients whose tumors were positive for at least one HR had a pCR rate of 15.9% (95% CI 8.7-25.6), and patients who were HR negative had a pCR rate of 17.8% (95% CI 8.0-32.1). Patients receiving AC-D had different pCR rates by HR status: patients with HR-positive disease had a pCR rate of 7.8% (95% CI 2.9-16.2) and those with HR-negative disease had a pCR rate of 42.9% (95% CI 27.7-59.0). Radiological response rates in the AP-D group were 58.6% (95% CI 47.6-69.1) for HR-positive patients and 61.4% (95% CI 45.5-75.6) for HR-negative Table 5 . The most common grade 3 or 4 non-hematologic toxicities were nausea (1.3%) and fatigue (1.1%) in the AP-D group and asthenia (1.4%) and hyperglycemia (1.1%) in the AC-D group. The rates of hematologic toxicities were low in both treatments arms. In the AP-D group, there were two grade 4 thrombocytopenias during the AP sequence and one grade 4 anemia during the docetaxel sequence. In the AC-D group, no grade 3 or 4 anemia or thrombocytopenia occurred. The rates of grade 3 or 4 neutropenia were similar in both treatment arms (see Table 5 ). Grade 3 or 4 febrile neutropenia occurred in five AP-D cycles and nine AC-D Because full dose was required for cycles 1 and 5, number of cycles in this row only refers to cycles 2-4 and 6-8. b Neutropenia caused four dose reductions of C and five dose reductions of P in the AC and AP cycles, respectively. c Because delays only occurred in cycles 2-8, cycle 1 is excluded from this row.
A, doxorubicin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; C, cyclophosphamide; D, docetaxel; P, pemetrexed. AC-D, doxorubicin plus cyclophosphamide followed by docetaxel; AP-D, doxorubicin plus pemetrexed followed by docetaxel; CI, confidence interval; CIS, carcinoma in situ; CR, complete response; pCR, pathological complete response; PD, progressive disease; pINV, residual invasive malignancy; PR, partial response; SD, stable disease. 
discussion
Within this international, multicenter, randomized, open-label phase II study, major prognostic factors like tumor stage, HR status, and HER2 status were equally distributed between treatment arms. Slight differences were seen in tumor grade, with grade 3 most common in the AP-D arm and grade 2 most common in the AC-D arm. Patients in the current study were younger (median age 49 years) and were more often premenopausal (52.5%) as compared with the average patient with primary breast cancer [33] , which confers a higher risk of relapse and death [8, 18, 34] . This study was not powered for statistical comparisons between treatment groups. Nonetheless, with respect to radiological response, the distribution of CRs and PRs was similar between groups. AP-D had a CR rate of 14.5% and a PR rate of 45.0%. AC-D had a CR rate of 17.6% and a PR rate of 50.4%. Responses were observed in both treatment arms following the first sequence of chemotherapy. After the first four cycles, response rate for AP was 40.5% and that for AC was 43.7%, which suggests that AP could have a similar clinical activity to AC.
Regarding pathological response, AP-D and AC-D both demonstrated promising efficacy by achieving pCR rates of 16.5% (95% CI 10.5-24.2) and 20.2% (95% CI 13.4-28.5), respectively. Following neoadjuvant chemotherapy, 53% of patients had no axillary lymph node involvement. Disease-free survival information is currently not mature. pCR in breast and axillary lymph nodes, however, correlates with improved disease-free and overall survival [2, 35] .
The pCR rates observed in this study are in the range of those observed in three large phase III studies of similar patient populations that employed neoadjuvant treatment with only four cycles of doublet combinations, such as epirubicin plus paclitaxel (AGO study), doxorubicin plus docetaxel (GEPARDUO study), and AC (NSABP B-18 and B-27 studies), which were associated with pCR rates between 10% and 14% [8, 12, 18, 36] . In contrast, pCR rates within this trial are slightly lower than the pCR rates of 26.1% achieved in the AC-D arm of NSABP B-27 and of 26.7% achieved with dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) in the PREPARE trial [34] . This might be due to differences in patient population rather than differences in the efficacy of treatment regimens.
In the current trial, patients were prospectively stratified according to their HR status. Among patients who were negative for both HRs, AC-D resulted in a pCR rate of 42.9% (95% CI 27.7-59.0). This compares with a pCR rate of 17. von Minckwitz et al. [37] recently presented a meta-analysis that included 6634 patients enrolled in cooperative neoadjuvant trials between 1998 and 2006 that included an anthracycline and a taxane [37] . This meta-analysis found that pCR rates were 7.8% among patients positive for both HRs (ER and PgR), 13.1% among those who were positive for one HR, and 24.3% among those who were negative for both HRs [37] . By this standard, AC-D appears especially promising among receptornegative patients.
In contrast, it is possible that the activity of pemetrexed is unrelated to HR status. The results of the current study are consistent with a previous phase II study in advanced breast cancer reported by Gomez et al. [25] , which did not show any difference in response rates by HR status. Given the promising pCR rate of AP-D in HR-positive EBC patients, additional phase III studies to further investigate this regimen in this patient population are warranted. In addition to the HR expression, the extensive translational companion program of this study searching for predictive molecular markers at the transcriptome level may provide additional information to define subgroups of patients who benefit most from this specific neoadjuvant chemotherapy regimen. This study component has been described previously [27] , and detailed results will be communicated in a forthcoming article. original article
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Both AP-D and AC-D were well tolerated and can be safely administered as neoadjuvant chemotherapy in EBC, as no unexpected quantitative or qualitative toxic effects were documented. There were no major differences between the toxicity profiles of both regimens. Most patients were able to receive all courses of therapy. The mean number of cycles administered was 7.4 for AP-D and 7.6 for AC-D.
In summary, AP-D and AC-D are well tolerated and are active as neoadjuvant chemotherapy in EBC. Of note, whereas AC-D seems to be more active in HR-negative tumors, but less active in HR-positive tumors, AP-D shows comparable activity in HR-positive and HR-negative tumors. This promising result warrants further evaluation within a phase III trial.
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